Literature DB >> 10361235

Depletion of liver and splenic macrophages reduces the lethality of Shiga toxin-2 in a mouse model.

M S Palermo1, M F Alves Rosa, N Van Rooijen, M A Isturiz.   

Abstract

The haemolytic uraemic syndrome (HUS) is a clinical syndrome consisting of haemolytic anaemia, thrombocytopenia, and acute renal insufficiency. HUS is the most frequent cause of acute renal failure in childhood. It has been previously suggested that the presence of Shiga toxin (Stx) is necessary but not sufficient for HUS development, and cytokines such as tumour necrosis factor-alpha (TNF-alpha) and IL-1beta appear to be necessary to develop the syndrome. Since the mononuclear phagocytic system (MPS) is the major source of these cytokines, macrophages might be one of the relevant targets for Stx action in the pathophysiology of HUS. In this study our objective was to examine the role of the hepatic and splenic macrophages in a mouse model of HUS induced by injection of Shiga toxin type-2 (Stx2) or Stx2 plus lipopolysaccharide (LPS). For this purpose, depletion of mice macrophages by liposome-encapsulated clodronate (lip-clod), followed by injection of STx2 or Stx2 plus LPS, was assayed. In this study we show that depletion of hepatic and splenic macrophages by clodronate treatment induces a survival of 50% in animals treated with Stx2 alone or in presence of LPS. This maximal effect was observed when lip-clod was injected 48-72 h before Stx2 injection. Biochemical and histological parameters show characteristics of the lesion produced by Stx2, discarding non-specific damage due to LPS or lip-clod. In addition, we determined that the toxic action of Stx2 is similar in BALB/c and N:NIH nude mice, indicating the T cell compartment is not involved in the Stx2 toxicity. Briefly, we demonstrate that macrophages play a central role in the pathophysiology of HUS, and that the systemic production of cytokines by liver and/or spleen is for Stx2 to manifest its full cytotoxic effect. In addition, the toxicity of Stx2 alone, or in presence of LPS, is independent of the T cell compartment.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10361235      PMCID: PMC1905309          DOI: 10.1046/j.1365-2249.1999.00925.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  42 in total

Review 1.  Divergent roles for Fc receptors and complement in vivo.

Authors:  J V Ravetch; R A Clynes
Journal:  Annu Rev Immunol       Date:  1998       Impact factor: 28.527

2.  Role of Shiga toxin in the pathogenesis of bacillary dysentery, studied by using a Tox- mutant of Shigella dysenteriae 1.

Authors:  A Fontaine; J Arondel; P J Sansonetti
Journal:  Infect Immun       Date:  1988-12       Impact factor: 3.441

3.  Macrophage growth factor CSF-1 stimulates human monocyte production of interferon, tumor necrosis factor, and colony stimulating activity.

Authors:  M K Warren; P Ralph
Journal:  J Immunol       Date:  1986-10-01       Impact factor: 5.422

4.  Renal histopathology in the hemolytic-uremic syndrome following shigellosis.

Authors:  F T Koster; V Boonpucknavig; S Sujaho; R H Gilman; M M Rahaman
Journal:  Clin Nephrol       Date:  1984-02       Impact factor: 0.975

5.  Elimination of phagocytic cells in the spleen after intravenous injection of liposome-encapsulated dichloromethylene diphosphonate. An enzyme-histochemical study.

Authors:  N van Rooijen; R van Nieuwmegen
Journal:  Cell Tissue Res       Date:  1984       Impact factor: 5.249

6.  Hemolytic-uremic syndrome after shigellosis. Relation to endotoxemia and circulating immune complexes.

Authors:  F Koster; J Levin; L Walker; K S Tung; R H Gilman; M M Rahaman; M A Majid; S Islam; R C Williams
Journal:  N Engl J Med       Date:  1978-04-27       Impact factor: 91.245

7.  Molecular cloning of the complementary DNA for human tumor necrosis factor.

Authors:  A M Wang; A A Creasey; M B Ladner; L S Lin; J Strickler; J N Van Arsdell; R Yamamoto; D F Mark
Journal:  Science       Date:  1985-04-12       Impact factor: 47.728

8.  Human granulocyte-macrophage colony-stimulating factor induces expression of the tumor necrosis factor gene by the U937 cell line and by normal human monocytes.

Authors:  S A Cannistra; A Rambaldi; D R Spriggs; F Herrmann; D Kufe; J D Griffin
Journal:  J Clin Invest       Date:  1987-06       Impact factor: 14.808

9.  Hemorrhagic colitis associated with a rare Escherichia coli serotype.

Authors:  L W Riley; R S Remis; S D Helgerson; H B McGee; J G Wells; B R Davis; R J Hebert; E S Olcott; L M Johnson; N T Hargrett; P A Blake; M L Cohen
Journal:  N Engl J Med       Date:  1983-03-24       Impact factor: 91.245

10.  The association between idiopathic hemolytic uremic syndrome and infection by verotoxin-producing Escherichia coli.

Authors:  M A Karmali; M Petric; C Lim; P C Fleming; G S Arbus; H Lior
Journal:  J Infect Dis       Date:  1985-05       Impact factor: 5.226

View more
  10 in total

1.  Monocyte chemoattractant protein 1, macrophage inflammatory protein 1 alpha, and RANTES recruit macrophages to the kidney in a mouse model of hemolytic-uremic syndrome.

Authors:  Tiffany R Keepers; Lisa K Gross; Tom G Obrig
Journal:  Infect Immun       Date:  2007-01-12       Impact factor: 3.441

2.  Shiga toxin binding to isolated porcine tissues and peripheral blood leukocytes.

Authors:  Kellie R K Winter; William C Stoffregen; Evelyn A Dean-Nystrom
Journal:  Infect Immun       Date:  2004-11       Impact factor: 3.441

3.  Administration of ricin induces a severe inflammatory response via nonredundant stimulation of ERK, JNK, and P38 MAPK and provides a mouse model of hemolytic uremic syndrome.

Authors:  Veselina Korcheva; John Wong; Christopher Corless; Mihail Iordanov; Bruce Magun
Journal:  Am J Pathol       Date:  2005-01       Impact factor: 4.307

4.  Cytokine production is altered in monocytes from children with hemolytic uremic syndrome.

Authors:  Gabriela C Fernández; María V Ramos; Veronica I Landoni; Leticia V Bentancor; Romina J Fernández-Brando; Ramón Exeni; María Del Carmen Laso; Andrea Exeni; Irene Grimoldi; Martín A Isturiz; Marina S Palermo
Journal:  J Clin Immunol       Date:  2012-01-08       Impact factor: 8.317

5.  Impaired neutrophils in children with the typical form of hemolytic uremic syndrome.

Authors:  Gabriela C Fernández; Sonia A Gómez; Carolina J Rubel; Leticia V Bentancor; Paula Barrionuevo; Marta Alduncín; Irene Grimoldi; Ramón Exeni; Martín A Isturiz; Marina S Palermo
Journal:  Pediatr Nephrol       Date:  2005-06-07       Impact factor: 3.714

Review 6.  Pathogenic role of inflammatory response during Shiga toxin-associated hemolytic uremic syndrome (HUS).

Authors:  Ramon Alfonso Exeni; Romina Jimena Fernandez-Brando; Adriana Patricia Santiago; Gabriela Alejandra Fiorentino; Andrea Mariana Exeni; Maria Victoria Ramos; Marina Sandra Palermo
Journal:  Pediatr Nephrol       Date:  2018-01-25       Impact factor: 3.714

7.  Shiga toxin-2 results in renal tubular injury but not thrombotic microangiopathy in heterozygous factor H-deficient mice.

Authors:  D Paixão-Cavalcante; M Botto; H T Cook; M C Pickering
Journal:  Clin Exp Immunol       Date:  2009-02       Impact factor: 4.330

8.  Mouse model of hemolytic-uremic syndrome caused by endotoxin-free Shiga toxin 2 (Stx2) and protection from lethal outcome by anti-Stx2 antibody.

Authors:  Kristin A D Sauter; Angela R Melton-Celsa; Kay Larkin; Megan L Troxell; Alison D O'Brien; Bruce E Magun
Journal:  Infect Immun       Date:  2008-08-11       Impact factor: 3.441

9.  Characterization of the cytokine immune response in children who have experienced an episode of typical hemolytic-uremic syndrome.

Authors:  Soeren Westerholt; Anne-Kathrin Pieper; Martin Griebel; Hans-Dieter Volk; Thomas Hartung; Renate Oberhoffer
Journal:  Clin Diagn Lab Immunol       Date:  2003-11

10.  Endogenous glucocorticoids attenuate Shiga toxin-2-induced toxicity in a mouse model of haemolytic uraemic syndrome.

Authors:  S A Gómez; G C Fernández; S Vanzulli; G Dran; C Rubel; T Berki; M A Isturiz; M S Palermo
Journal:  Clin Exp Immunol       Date:  2003-02       Impact factor: 4.330

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.